Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02046941 · ClinicalTrials.gov registry record · NA

Brain Biomarkers of Response to Treatment for Apraxia of Speech

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
17
Enrollment target

NCT02046941: Completed NA study, sponsored by VA Office of Research and Development.

NCT02046941 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02046941, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target

Study Summary

The study will use MRI brain imaging to identify brain changes associated in stroke patients after they receive speech-language treatment for their speech difficulties.

Primary Outcome

For each participant, three target sounds were chosen: single consonants, vowels, or clusters at the word level. Based on these target sounds, 10 word items were generated for each target sound that served as Trained Items. Participants were tested on lists of Trained Items (probe trials) during repeated sessions in pre-intervention stage to establish baseline performance (percent of each word list repeated correctly) and during every other treatment session (again, percent of each word list rep

Interventions

  • BEHAVIORAL Speech Production Treatment

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2014-03-01
Est. Completion 2018-06-30
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02046941 record still lists

NCT02046941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Speech Production Treatment is the first listed.

NCT02046941 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02046941 about?

NCT02046941 is a clinical study titled "Brain Biomarkers of Response to Treatment for Apraxia of Speech". The study will use MRI brain imaging to identify brain changes associated in stroke patients after they receive speech-language treatment for their speech difficulties.

What is the current status of trial NCT02046941?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2014-03-01. Estimated completion is 2018-06-30.

What interventions are being tested in trial NCT02046941?

The interventions under investigation include: Speech Production Treatment (BEHAVIORAL).

Who is sponsoring clinical trial NCT02046941?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02046941's enrollment target sits among peer trials

17 1871st of 2000 higher than 130 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02046941, the US trial registry maintained by the National Library of Medicine. NCT02046941 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.